Trial
NCT02977689
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
NYU Langone Health
Collaborators
Novartis
Condition
Glioma
Intervention
IDH305
Why stopped
Novartis paused all study start-up activities due to safety evaluation of IDH305 compound.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-20